- Created on 01-30-2013
Prostate cancer is associated with lower bone density, increased fractures and it can metastasize to the bones. In addition, treatment for prostrate cancer (androgen deprivation therapy) causes reductions in the important bone protective hormones - testosterone and estrogen. This decrease in testosterone and estrogen results in rapid loss of bone density, decreased muscle mass, and increased fractures.
Doctors have been treating prostrate cancer patients with bisphosphonates to prevent bone loss. In particular, zolendronic acid (brand name Reclast) has been the treatment of choice. A recent study from the UK shows that one of the newer osteoporosis treatments, Denosumab (brand name Prolia) both increases bone density and reduces fracture rates. Prostate cancer also commonly metastasizes to bone where it can cause complications such as fracture and pain.
Prostate cancer is a very common cancer and survival rates are increasing. This means that men with prostrate cancer need to be vigilant about preventing bone loss with proper treatment and prevention strategies.